M3, Inc.

COVID-19 Pneumonia AI Free Provision Project Expansion
and Exacerbation Prediction AI Development


M3 Inc. (Headquarter: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; "M3," below) has announced a new project in effort to support medical sites across Japan in fighting COVID-19 long-term.

1. Free COVID-19 Pneumonia AI Remote Diagnosis Service Provision Expansion

Free remote AI medical image diagnosis support, such as the "COVID-19 Pneumonia Image Analysis Program Ali-M3," has been provided since its approval by the MHLW on June 29. Since then, we have received numerous applications for this service, which is now expected to be utilized across 121 medical sites. Roughly 10,000 medical images have already been analyzed to date. This project is being funded by Sony's Global Relief Fund for COVID-19.

Given the influx of requests from medical sites, we will be extending this free service provision project, support from Mitsui Sumitomo Financial Group and Pfizer Inc.

The service will be provided free of charge for a limited time by M3's AI Lab and NOBORI Ltd. (CEO: Yoshihisa Yoda; Headquarter: Tokyo, Japan). The medical sites will connect their PACS systems to M3's Edge Server (M3's AI Platform) in order to remotely utilize the COVID-19 Pneumonia Image Analysis AI. We hope that this will serve the medical community in the upcoming winter months.

2. COVID-19 Exacerbation Prediction AI Development

We have launched the development and evaluation of an exacerbation prediction model, in collaboration with the University of Hyogo and the Hyogo Prefectural Amagasaki General Medical Center, along with CT imaging and clinical data from 11 medical sites. This model will be designed to predict the risk for exacerbation and prognosis for a COVID-19 patient, and therefore contribute to the reduction of aggravated cases, as well as support medical sites to prepare with appropriate resources.

Support from Mitsui Sumitomo Financial Group will allow us to continue this project.